ITCH AND THE MICROBIOME

The presentation focuses on the critical role of the microbiome in dermatology, particularly how it relates to itch, a complex phenomenon often overlooked in skin conditions. The speaker emphasizes that pruritus results from a dynamic interplay between immune cells, sensory neurons, and microbial interactions, notably with Staphylococcus aureus (staph aureus). Conditions such as atopic dermatitis create an environment conducive for staph aureus, which exacerbates chronic itching by disrupting the skin barrier and stimulating inflammation. Recent studies indicate that therapies like dupilumab effectively reduce staph aureus colonization while improving skin barrier function and lipid metabolism, illustrating the potential for targeted microbiome-friendly treatments. Additionally, the talk addresses other skin disorders, like prurigo nodularis and cutaneous T-cell lymphoma (CTCL), proposing that itch may contribute to disease progression. The importance of exploring alternative therapies, such as prebiotics, bacteriophage therapy, and microbiome transplants, is highlighted to manage microbial dysbiosis without adversely affecting the skin microbiome. The presenter calls for further research into how current treatments affect skin microbiome dynamics and recommends integrating microbiome analysis into clinical practice.